Behavioral Modification and Lorcaserin for Overweight and Obesity Management - BLOOM


Activation of 5-HT2C receptors (serotoninergic) has been shown to be associated with decreased food intake in basic science studies. An earlier phase II trial involving lorcaserin, a selective 5-HT2C receptor agonist, demonstrated dose-dependent weight loss with its use. BLOOM was a phase III trial designed to study the safety and efficacy of lorcaserin for weight management in obese patients.